News
-
2020-09 20MORE
3D Medicines Announced the Publication of
September 20, 2020, Beijing, China – 3D Medicines announced the publication of "the results of a single arm, pivotal, multicenter, phase II study to evaluate the efficacy and safety of Envafolimab (KN035) monotherapy in dMMR/MSI-H advanced cancer" on Chinese Society of Clinical Oncology (CSCO) annual meeting. Envafolimab (KN035) is a next-generation PD-L1 antibody, on which 3D Medicines Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Simcere Pharmaceuticals reached a strategic collaboration.
-
2020-05 29MORE
Latest Clinical Trial Results for Subcutaneous PD-L1 Antibody Envafolimab（KN035）Published on ASCO 2020 Annual Meeting
Beijing, China, May 29, 2020 - 3D Medicines, Inc.，a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated next-generation immuno-oncology drugs, today published the latest clinical trial results for Subcutaneous PD-L1 Antibody Envafolimab（KN035）on the 2020 annual meeting of American Society of Clinical Oncology (ASCO), under the title of “Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency”.
-
2020-05 29MORE
3D Medicines Announced Clinical Trial Data for Subcutaneous PD-L1 Antibody KN035 Would Be Published on ASCO 2020 Annual Meeting
Beijing, China, May 29, 2020 - 3D Medicines announced that the data from two clinical trials on Envafolimab (KN035) will be published on the 2020 annual meeting of American Society of Clinical Oncology (ASCO).
